High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation

Wille K, Sadjadian P, Becker T, Kolatzki V, Horstmann A, Fuchs C, Griesshammer M (2019)
ANNALS OF HEMATOLOGY 98(1): 93-100.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor/in
; ; ; ; ; ;
Abstract / Bemerkung
Venous thromboembolism (VTE) is a major burden in patients with BCR-ABL-negative myeloproliferative neoplasms (MPN). In addition to cytoreductive treatment anticoagulation is mandatory, but optimal duration of anticoagulation is a matter of debate. In our single center study, we retrospectively included 526 MPN patients. In total, 78 of 526 MPN patients (14.8%) had 99 MPN-associated VTE. Median age at first VTE was 52.5years (range 23-81). During a study period of 3497years, a VTE event rate of 1.7% per patient/year was detected. 38.4% (38/99) of all VTEs appeared before or at MPN diagnosis and 55.6% (55/99) occurred at uncommon sites like splanchnic or cerebral veins. MPN patients with VTEs were significantly more female (p=0.028), JAK2 positive (p=0.018), or had a polycythemia vera (p=0.009). MPN patients without VTEs were more often CALR positive (p=0.023). Total study period after first VTE was 336years with 20 VTE recurrences accounting for a recurrence rate of 6% per patient/year. In 36 of 71 MPN patients with anticoagulation therapy after first VTE event (50.7%), prophylactic anticoagulation was terminated after a median time of 6months (range 1-61); 13 of those 36 patients (36.1%) had a VTE recurrence after a median of 13months (range 4-168). In contrast, only three of 35 (8.6%) patients with ongoing anticoagulation had a VTE recurrence (p=0.0127). Thus, termination of prophylactic anticoagulation was associated with a significantly higher risk of VTE recurrence. Our data suggest that in MPN patients with VTE, a prolonged duration of anticoagulation may be beneficial.
Erscheinungsjahr
2019
Zeitschriftentitel
ANNALS OF HEMATOLOGY
Band
98
Ausgabe
1
Seite(n)
93-100
ISSN
0939-5555
eISSN
1432-0584
Page URI
https://pub.uni-bielefeld.de/record/2933522

Zitieren

Wille K, Sadjadian P, Becker T, et al. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY. 2019;98(1):93-100.
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Horstmann, A., Fuchs, C., & Griesshammer, M. (2019). High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY, 98(1), 93-100. doi:10.1007/s00277-018-3483-6
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Horstmann, A., Fuchs, C., and Griesshammer, M. (2019). High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY 98, 93-100.
Wille, K., et al., 2019. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY, 98(1), p 93-100.
K. Wille, et al., “High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation”, ANNALS OF HEMATOLOGY, vol. 98, 2019, pp. 93-100.
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Horstmann, A., Fuchs, C., Griesshammer, M.: High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY. 98, 93-100 (2019).
Wille, Kai, Sadjadian, Parvis, Becker, Tatjana, Kolatzki, Vera, Horstmann, Anette, Fuchs, Christiane, and Griesshammer, Martin. “High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation”. ANNALS OF HEMATOLOGY 98.1 (2019): 93-100.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 30155552
PubMed | Europe PMC

Suchen in

Google Scholar